Sign In
Buy SCYX
$4.67
-0.430 (-8.43%)
At Close: Jun 03, 2026
SCYNEXIS Announces One-for-Eight Reverse Stock Split
04:15pm, Friday, 22'nd May 2026
SCYNEXIS's Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026 SCYNEXIS's Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
04:23pm, Monday, 11'th May 2026
JERSEY CITY, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today re
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
09:15pm, Wednesday, 06'th May 2026
JERSEY CITY, N. J. , May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) ("SCYNEXIS" or the "Company"), a biotechnology company focused on developing innovative new therapies to address sev
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
09:15pm, Wednesday, 06'th May 2026
JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to addre
SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript
04:42pm, Tuesday, 31'st Mar 2026
SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
07:06am, Tuesday, 31'st Mar 2026
LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with
SCYNEXIS Announces $40.0 Million Private Placement
06:45am, Tuesday, 31'st Mar 2026
JERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to
PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the underlying drivers of ADPKD by reducing cyst growth and disease progression A Phase 2 proof-of-concep
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
04:20pm, Wednesday, 04'th Mar 2026
JERSEY CITY, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resist
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
08:23am, Thursday, 26'th Feb 2026
JERSEY CITY, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resista
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
08:00am, Tuesday, 17'th Feb 2026
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing n
Financial Survey: SCYNEXIS (NASDAQ:SCYX) and KalVista Pharmaceuticals (NASDAQ:KALV)
01:58am, Monday, 16'th Feb 2026
KalVista Pharmaceuticals (NASDAQ: KALV - Get Free Report) and SCYNEXIS (NASDAQ: SCYX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the tw
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
08:00am, Monday, 22'nd Dec 2025
JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK
07:00am, Wednesday, 19'th Nov 2025
JERSEY CITY, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
04:20pm, Wednesday, 05'th Nov 2025
JERSEY CITY, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resista
